CD274 and non-small cell lung carcinoma: Therefore, both molecular and clinical criteria should be considered in the decision-making tree of non-squamous NSCLC patients, including PD-L1 expression and clinical factors associated with higher probability of response to nintedanib plus docetaxel (early progression or resistance to first-line therapy, high disease burden) or lower probability of response to nivolumab (progression disease as best response to prior treatment, early progression, five or more sites with lesions, bone or hepatic metastases, non-smoker status) (Fig. 1) [16, 17].